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Information about current guideline 1 
This guideline covers the diagnosis and management of malaria, and was 2 
published in the Journal of Infection in June 2016.[1] It was written by the 3 
Public Health England Advisory Committee on Malaria Prevention (PHE 4 
ACMP) based on review of available evidence and expert consultation (using 5 
a modified GRADE criteria for assessment of evidence and strength of 6 
recommendation), to be in line with World Health Organization guidelines on 7 
management of malaria.[2] It relates to malaria in both adults and children in 8 
the UK although here we focus on the diagnosis and management of children 9 
returning to the UK with suspected malaria. Malaria is the most common 10 
imported tropical pathogen in the UK, and children comprise about 10% of the 11 
1300-1800 UK cases per annum. Plasmodium falciparum is by far the most 12 
common (around 75% of cases) and is associated with more severe disease. 13 
 14 
Previous guideline 15 
This guideline replaces the previous PHE ACMP UK malaria treatment 16 
guideline (2007),[3] and suggested guidance/recommendations from Maitland 17 
et al. (2005), which advocated more aggressive fluid resuscitation in severe 18 
malaria than now suggested.[4] 19 
 20 
RESOURCES (BOX) 21 
 http://www.journalofinfection.com/article/S0163-4453(16)00047-22 
5/fulltext Full guideline 23 
 https://www.ncbi.nlm.nih.gov/pubmed/26880088 Executive summary 24 
 http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.25 
pdf?ua=1&ua=1 World Health Organization (WHO) guidelines for the 26 
treatment of malaria (2015) 27 
 https://www.gov.uk/government/publications/malaria-prevention-28 
guidelines-for-travellers-from-the-uk Public Health England malaria 29 
prevention guidelines 30 
 http://travelhealthpro.org.uk Country-specific information on malaria 31 
 www.fitfortravel.nhs.uk Public access website providing health 32 
information for people travelling abroad from the UK 33 
 3 
 1 
Key issues that the guideline addresses 2 
 3 
When to suspect malaria? 4 
Malaria should be considered in any unwell or feverish child who has visited 5 
an endemic country regardless of whether prophylaxis was taken. P. 6 
falciparum usually presents within 1 month of exposure (minimum 6 days), 7 
although later presentations can occur. Other species may present over a 8 
year post-travel.  9 
 10 
Clinical Features 11 
Malaria in children can be notoriously non-specific, even without fever. 12 
Although fever, malaise and lethargy are the most common symptoms, 13 
children can present with gastrointestinal symptoms (including diarrhoea), 14 
jaundice, breathing difficulties or sore throat. Examination may reveal hepato- 15 
and/or splenomegaly and lethargy. 16 
 17 
Diagnosis 18 
Thick and thin blood films remain the gold standard for detection and 19 
speciation of malarial parasites, but rapid diagnostic tests (RDTs) are almost 20 
as accurate for P. falciparum and P. vivax. If there is ongoing clinical 21 
suspicion with negative blood films, these should be repeated at 12-24 hours 22 
and again after a further 24 hours, particularly if fever is persistent. Empirical 23 
therapy in the context of negative tests should only be given with symptoms of 24 
severe malaria and on expert advice. Thrombocytopaenia is common in 25 
children with malaria; although not diagnostic, it should increase the index of 26 
suspicion. 27 
 28 
Treatment  29 
Even in uncomplicated malaria, with P. falciparum there can be rapid 30 
deterioration during the first 24 hours of treatment, so admission is 31 
recommended initially. Uncomplicated P. falciparum malaria should be treated 32 
with oral artemisinin combination therapy (ACT), e.g. artemether-lumefatrine 33 
 4 
dosed according to weight (see BNF or Box 8 of guideline [1]). Admission will 1 
also ensure that the oral ACT is tolerated as some children can vomit. 2 
 3 
Features of severe malaria are: 4 
1. Cerebral malaria 5 
2. Respiratory distress/metabolic acidosis 6 
3. Severe anaemia 7 
4. Prostration (a child unable to sit if normally able to do so, or the inability 8 
to drink in a younger child) 9 
5. Hypoglycaemia 10 
6. Electrolyte disturbance 11 
7. Circulatory shock 12 
 13 
Severe malaria should be managed in a paediatric intensive care or high 14 
dependency unit with advice from a paediatric infectious diseases specialist 15 
with malaria expertise. Intravenous artesunate gives a clear survival 16 
advantage over quinine and is the drug of choice.[5] Following the results of 17 
the FEAST trial showing a detrimental effect of fluid boluses, fluid 18 
resuscitation should be cautious even in the context of shock.[6] Glucose 19 
monitoring is crucial, and broad spectrum antibiotics should be given until 20 
bacterial co-infection is excluded.  21 
 22 
For non-P. falciparum malaria, both ACT and chloroquine are effective for 23 
acute infection, although there is growing resistance to chloroquine in some 24 
Indonesian areas. ACT may clear parasites faster and covers for P. 25 
falciparum in case mixed infection cannot be excluded. To prevent relapse for 26 
P. vivax and P. ovale, primaquine treatment should overlap with ACT to 27 
ensure eradication of hypnozoites in the liver, after exclusion of G6PD 28 
deficiency.  29 
 30 
All children receiving intravenous artesunate need a repeat full blood count at 31 
2 weeks post-therapy as it is associated with delayed haemolysis. 32 
Families should be informed about mandatory notification of Public Health 33 
England, reassured that the child is not infectious to others (although other 34 
 5 
family members who also travelled may be at risk), and informed that 1 
relapse/recrudescence is a risk, and so medical attention should be sought 2 
with recurrent fevers. Finally, they should be directed to seek up to date 3 
advice on malarial prevention when travelling in future (see Resources box). 4 
 5 
UNDERLYING EVIDENCE BASE (BOX) 6 
 Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus 7 
quinine in the treatment of severe falciparum malaria in African children 8 
(AQUAMAT): an open-label, randomised trial. Lancet 2010;376:1647-9 
57.[5] 10 
 Maitland K, Kiguli S, Opoka RO, et al. Mortality after fluid bolus in 11 
African children with severe infection. N Engl J Med 2011;364:2483-12 
95.[6] 13 
 Meremikwu M, Smith HJ. Blood transfusion for treating malarial 14 
anaemia. Cochrane Database of Syst Rev 2000:CD001475.[7] 15 
 16 
What do I need to know? 17 
What should I start doing? 18 
1. Use intravenous artesunate instead of quinine for treatment of severe 19 
malaria [5] 20 
2. If intravenous artesunate is not immediately available, do not delay 21 
initiating treatment with intravenous quinine 22 
3. Use artesunate combination therapy (ACT) orally as first line treatment 23 
for uncomplicated malaria (both P. falciparum and non-P. falciparum) 24 
 25 
What should I not do? 26 
 Do not give rapid fluid boluses. For patients with shock, cautious and 27 
slow volume resuscitation should be used – the FEAST trial found an 28 
increased risk of death in children receiving crystalloid or colloid fluid 29 
boluses.[6] 30 
 Do not give routine blood transfusions except in severe anaemia, as 31 
they can increase adverse events without reducing mortality.[7] 32 
 33 
 6 
What should I continue doing as before? 1 
 Malaria should be suspected in anyone with a history of fever and 2 
return from a malaria endemic area even if prophylaxis was taken 3 
 Thick and thin blood smears are still the gold standard for diagnosis  4 
 Rapid diagnostic tests (RDT) detect parasite antigens, and are a useful 5 
addition to blood smears but can miss non-P. falciparum malaria 6 
 If there is ongoing clinical suspicion of malaria but the initial blood films 7 
are negative, two further films should be assessed 8 
 All children with malaria should have at least 24 hours of inpatient 9 
observation 10 
 Severe or complicated malaria should be managed in an intensive care 11 
or high dependency setting, with support from a paediatric infectious 12 
diseases specialist 13 
 Broad spectrum antibiotics should be used in addition to anti-malarial 14 
treatment until bacterial co-infection has been excluded 15 
 Notify all malaria cases to Public Health England 16 
 Remember eradication of liver stage hypnozoites with primaquine in P. 17 
vivax and P. ovale malaria 18 
 19 
Unresolved controversies 20 
1. Potential management of uncomplicated malaria as an outpatient 21 
Adults with P. ovale, P. vivax and P. malariae are often managed in an 22 
outpatient setting, and in specialist centres P. falciparum is sometimes 23 
managed in outpatients by experienced clinicians with clear protocols. In 24 
children, at least 24 hours of observation in hospital is recommended due to 25 
the risk of rapid deterioration and vomiting ACT. Data are currently lacking 26 
around the potential safety of more rapid discharge in the UK context. 27 
 28 
2. Three films to exclude malaria 29 
The evidence underlying the requirement of three negative films over a 36-48 30 
hour period to exclude malaria has recently been reviewed by Wilson et al.[8] 31 
Most published literature relates to adult data, but the combination of one 32 
blood film and one RDT is extremely sensitive for malaria. The authors 33 
 7 
concluded that it is safe to exclude malaria in a well-appearing, afebrile child 1 
with one negative RDT in addition to one negative blood film, although 2 
appropriate safety netting advice should be provided.[8] 3 
 4 
3. Definition of severe malaria in non-endemic countries 5 
The precise definitions of severe malaria, which predict morbidity or mortality, 6 
and which justify PICU admission or additional interventions such as blood 7 
transfusion, are not based on firm evidence from non-endemic populations. 8 
For example, whether a 2% parasitaemia in a child with otherwise 9 
uncomplicated malaria justifies PICU/HDU admission is widely debated. It is 10 
worth noting that the WHO guideline [2] has a more extensive list of severity 11 
features, including renal impairment, which is a strong predictor of death in 12 
African settings, and the addition of base excess <-8mEq/L or lactate 13 
>5mmol/L to the definition of acidosis. However, the relative importance of 14 
these features in the non-endemic setting remains unclear; the threshold for 15 
admission to PICU/HDU is likely to be dependent on the experience of the 16 
particular unit of managing malaria in children in the UK. 17 
 18 
CLINICAL BOTTOM LINE (BOX) 19 
 Malaria should be suspected in all children with fever and travel to a 20 
malaria endemic region 21 
 Children with severe/complicated malaria should be managed in an 22 
intensive care/high dependency setting 23 
 Intravenous artesunate should preferentially be used to treat 24 
severe/complicated malaria, and oral ACT for non-severe cases 25 
 Broad spectrum antibiotics should be used until bacterial co-infection 26 
has been excluded 27 
 Fluid resuscitation should be cautious 28 
 29 
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